interim results for bcma t-cell engager alnuctamab (cc-93269) in rrmm
Published 4 years ago • 78 plays • Length 2:24Download video MP4
Download video MP3
Similar videos
-
2:58
bcma 2 1 t-cell engager cc-93269 in patients with r/r myeloma
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
2:27
milestone trial results: mrd response-adapted deferral of autosct in newly diagnosed myeloma
-
5:52
bcma targeting agents in myeloma
-
21:38
drawing the line: the rationale behind blood tube collection order
-
40:09
corpuls defib training 2018 🚑
-
21:24
cell surface markers: cd3, cd4, cd8, cd19, cd28, cd16, cd56
-
1:45
targetting bcma in myeloma
-
3:41
teclistamab: bcma x cd3 bispecific antibody in rrmm
-
4:11
highlights from ims 2024: key clinical trials presented
-
2:09
heart transplantation in attr amyloidosis
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
2:16
the sequencing of novel therapies in myeloma (car-t, bispecifics, antibody-drug conjugates)
-
2:46
subcutaneous alnuctamab in patients with r/r multiple myeloma: the results of a phase i trial
-
1:52
evaluating surrogacy endpoints in cll clinical trials
-
2:38
the value of subcutaneous alnuctamab for the treatment of r/r multiple myeloma
-
2:07
aspire update: promising results for mm
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
0:54
azintuxizumab vedotin for r/r multiple myeloma
-
2:11
future myeloma treatment strategies